Communiqués KDA Group Inc.

Actions

KDA

CA48669F1071

Logiciels

Marché Fermé - Toronto S.E. 15:30:00 15/09/2026			Varia. 5j.	Varia. 1 janv.
0,0800 ^CAD	+6,67%		0,00%	-66,67%

26/08	Groupe KDA nomme Louise Potvin à son conseil d'administration	MT
26/08	Groupe KDA Inc. annonce des changements au sein de son conseil d'administration	CI

Communiqués

26/08	KDA GROUP APPOINTS LOUISE POTVIN TO ITS BOARD OF DIRECTORS	AQ
18/06	AN INDEPENDENT EVALUATION CONFIRMS THE CLINICAL AND ORGANIZATIONAL BENEFITS OF THE MEDHERIZE PLATFORM IN BREAST ONCOLOGY	AQ
30/05	KDA GROUP COMPLETES DEBT SETTLEMENT	AQ
05/05	KDA GROUP ANNOUNCES RESULTS OF SHAREHOLDERS' ANNUAL GENERAL MEETING AND THE SETTLEMENT OF JUDICIAL CLAIMS	AQ
09/04	KDA GROUP ANNOUNCES THE APPOINTMENT OF MARTIN KIROUAC AS CHIEF TECHNOLOGY OFFICER OF ITS SUBSIDIARY GROUPE TECHNOLOGIQUE KDA	AQ
24/03	KDA GROUP ANNOUNCES THE ACQUISITION OF THE MINORITY INTEREST IN ITS SUBSIDIARY GROUPE TECHNOLOGIQUE KDA INC.	AQ
02/03	KDA ANNOUNCES THE APPOINTMENT OF A NEW PRESIDENT AND CHIEF EXECUTIVE OFFICER	AQ
24/12	UPDATE OF THE TRANSACTION ANNOUNCED ON NOVEMBER 25, 2025, FOR THE ACQUISITION OF THE MINORITY INTEREST IN THE SUBSIDIARY GROUPE TECHNOLOGIQUE KDA INC.	AQ
22/12	KDA GROUP ANNOUNCES A COLLABORATION TO INTEGRATE NEW CLINICAL ALERTS INTO THE MEDHERIZE PLATFORM TO SUPPORT THE ADOPTION OF NEXT-GENERATION SEQUENCING FOR BREAST CANCER PATIENTS	AQ
03/12	KDA GROUP ANNOUNCES PARTNERSHIP AGREEMENT WITH CHU DE QUÉBEC-UNIVERSITÉ LAVAL FOR THE DEPLOYMENT OF MEDHERIZE	AQ
01/12	KDA GROUP DEPLOYS MEDHERIZE ACROSS COMMUNITY PHARMACIES: A MAJOR STEP FORWARD IN THE MANAGEMENT OF ORAL ANTICANCER THERAPIES	AQ
25/11	KDA GROUP ANNOUNCES AGREEMENT TO ACQUIRE MINORITY INTEREST IN ITS SUBSIDIARY GROUPE TECHNOLOGIQUE KDA INC.	AQ
17/11	KDA GROUP OPENS A U.S. SUBSIDIARY AND ACCELERATES THE GROWTH OF ITS MEDHERIZE SOLUTION	AQ
29/05/25	KDA GROUP ANNOUNCES CLOSING OF PRIVATE PLACEMENT	AQ
21/05/25	KDA GROUP RECEIVES DSQ CERTIFICATION FOR ADHERIZE+ PLATFORM -- MEDHERIZE MODULE ENTERS CLINICAL DEPLOYMENT PHASE	AQ
15/04/25	KDA GROUP REACHES FINAL CERTIFICATION PHASE FOR MEDHERIZE WITH DSQ - DOSSIER SANTÉ QUÉBEC	AQ
24/02/25	KDA GROUP ANNOUNCES RESULTS OF SHAREHOLDERS' ANNUAL GENERAL MEETING	AQ
12/12/24	GROUPE TECHNOLOGIQUE KDA ANNOUNCES A STRATEGIC COLLABORATION WITH PHARMACIE HORIZON SANTÉ AND DR. ÉRIC POIRIER TO OPTIMIZE ONCOLOGY TREATMENT MANAGEMENT	AQ
03/12/24	KDA Group Announces an Important Certification Update with the Quebec Health Record / Dossier Sante Quebec	AQ
21/11/24	KDA Group Announces the Appointment of the Honorable Jean Charest as New Strategic Advisor	AQ
01/08/24	KDA Group Launches Medherize for Specialized Metastatic Breast Cancer Treatment Management	AQ
12/06/24	KDA Group Announces the Development of Medherize, a New Clinical Management Solution for Specialized Medications for Breast Cancer	AQ
18/05/24	KDA Group Announces Results of Shareholders' Annual General and Special Meeting	AQ
21/03/24	Adherize+ Platform Update	AQ
29/02/24	KDA Group Completes Debt Settlement	AQ